Who
Owen Hughes
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, XOMA Royalty; Director, C4 Therapeutics; Director, AnaptysBio; Director, ImageneBio; Director, Radius Health; Director, Pardes Biosciences; Director, Translate Bio; President and CEO, Cullinan Therapeutics.
In numbers
- Trades disclosed
- 88
- Buys
- 7
- Sells
- 5
- Bought
- $2.7M
- Sold
- $2.5M
- Companies
- 8
- Companies where not an officer
- 6
- First trade
- 5 Jun 2014
- Last trade
- 14 Jul 2026
- Last filed
- 14 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 14 Jul 2026filed 14 Jul 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code J | —191,264 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code J | —752 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code D | —102,000 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —100,000 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —75,000 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —116,245 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative | SEC FORM 4 Code D | —132,714 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —100,000 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —75,000 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —116,245 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code D | —132,714 at $0.00 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royalty | SEC FORM 4 Code J | —191,264 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royalty | SEC FORM 4 Code J | —752 | filing |
| 14 Jul 2026filed 14 Jul 2026 | XOMA Royalty | SEC FORM 4 Code D | —102,000 | filing |
| 24 Jun 2026filed 26 Jun 2026 | CCCC C4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,000 at $0.00 | filing |
| 24 Jun 2026filed 26 Jun 2026 | CCCC C4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —62,000 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —11,250 at $0.00 | filing |
| 11 May 2026filed 13 May 2026 | ANAB AnaptysBiooption or derivative · Biotechnology | SEC FORM 4 Code A | —11,250 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | XOMA RoyaltyBiotechnology | SEC FORM 4 Code M | —10,568 at $0.00 | filing |
| 20 Apr 2026filed 22 Apr 2026 | XOMA Royaltyoption or derivative · Biotechnology | SEC FORM 4 Code M | —10,568 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.